De‐escalating medical therapy in Crohn’s disease patients who are in deep remission: A RAND appropriateness panel

Abstract

Summary Background Deep remission is a treatment goal for patients with Crohn's disease, after which de‐escalation of medical therapy may be considered. However, applicability of available study data to real‐world clinical practice can be challenging. Aim We evaluated the appropriateness of de‐escalating immunomodulator or anti‐tumour necrosis factor therapy in Crohn's disease patients in deep remission. Methods A literature review was presented to a panel of international experts in Crohn's disease. Appropriateness of de‐escalation in patients in deep remission for at least 6 months was considered in 240 scenarios across five chapters. Using a modified Delphi method, panel members rated appropriateness of de‐escalation in each scenario via a web‐based survey, then met to discuss the topic and re‐rated the scenarios. Scenarios with disagreement were rated as uncertain. Results De‐escalation was rated appropriate in only 32/240 scenarios (13.3%), including 19 of elderly patients on combination therapy. De‐escalation was rated inappropriate in 59/240 scenarios (24.6%), including 22 of patients on monotherapy and 35 of patients on combination therapy stopping anti‐tumour necrosis factor therapy. More than 60% of scenarios (149/240) were rated uncertain, including 42 of patients with complicated disease on combination therapy stopping or dose‐reducing immunomodulators. Conclusions Discontinuing anti‐tumour necrosis factor or immunomodulator therapy was largely not recommended, except in scenarios of elderly patients with uncomplicated CD or those on combination therapy stopping or dose‐reducing immunomodulators. As nearly two‐thirds of scenarios were rated uncertain, additional data are needed to better inform clinicians regarding the benefits and risks of de‐escalating medical therapy in Crohn's disease.

Personalising therapy: de‐escalation in Crohn's disease patients who are in deep remission

“…While there is consensus on initiation immunomodulatory and biologics therapies in Crohn's disease, there is considerable disagreements among clinicians in relation to withdrawal of therapies particularly in relation to its timing, monitoring of patients following withdrawal and also the longer term safety and efficacy of withdrawal strategies. Hence the RAND appropriateness panel study by Sparrow et al in the current issue of the journal is both timely and relevant to practicing clinicians.…”

Prognostic tools for identification of high risk in people with Crohn’s disease: systematic review and cost-effectiveness study

“…Factors that need to be accounted for when considering de-escalation of therapy include age, sex, treatments given and severity of CD. 34 A systematic review 34 anti-tumour necrosis factor (TNF) or immunomodulator (IM) therapy in people with CD who were in deep remission for at least 6 months found that de-escalating medical therapy in this cohort was appropriate for a small proportion of carefully selected people only, predominantly the elderly and those with non-severe disease.…”

Improving IBD care: influences on physician and patient behaviour

“…Finally, should we de‐escalate treatment of IBD patients who are in “deep remission”? With limited studies available Sparrow et al reported on the findings of a RAND panel of international experts in Crohn's disease . This paper merits a critical commentary of its own …”

“…This issue of GastroHep features three papers on inflammatory bowel diseases (IBD) . The first paper by Cristina Bezzio et al looks into the barriers to anti‐TNFalpha prescription among Italian physicians managing inflammatory bowel disease .…”